A recent study suggests that blocking the MYC protein could be “unexpectedly effective” in treating malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers.

Vanderbilt-Ingram Cancer Center Ambassadors surpassed the $1 million mark with the awarding of the group’s latest research grants.

As this year’s chair of the VICC Ambassadors, Ashley Larcinese, is driven by her experiences to see that research is funded at VICC.

Charles Caskey, Ph.D., has received a cancer research grant from The Mary Kay Foundation to study how focused ultrasound therapy could be an ideal helper for immunotherapy.

Henry Paul and Dave Robbins, members of country music group BlackHawk, as well as southern rock band The Outlaws, recently donated $40,000 to Vanderbilt-Ingram Cancer Center (VICC) in support of melanoma research.

Targeting specific molecules in breast tumors, called methylating agents, can turn up the immune response, potentially making tumors responsive to immunotherapy, suggests a new study published in Nature Communications.

Researchers at Vanderbilt University Medical Center (VUMC) have demonstrated for the first time that it is possible to starve a tumor and stop its growth with a newly discovered small compound that blocks uptake of the vital nutrient glutamine.

Cancer investigators led by researchers at Vanderbilt-Ingram Cancer Center have co-developed a liquid biopsy blood-based assay used to identify specific gene mutations associated with the development or relapse of small-cell lung cancer (SCLC)

Histone deacetylases (HDACs) are enzymes that modulate gene expression and have important roles in development and disease. HDAC inhibitors are active against lymphoma, and understanding the roles of specific HDACs is important for further therapeutic development. Scott Hiebert, Ph.